AstraZeneca plc vs Campbell Soup Co. — how do they compare? AstraZeneca plc trades at $157.99 (market cap $248.14B), while Campbell Soup Co. trades at $22.71 (market cap $6.78B). The key difference: AstraZeneca plc is far larger — about 36.6× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| AZN | CPB | |
|---|---|---|
Market Cap | $248.14B | $6.78B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $34.03 |
52-Week Low | $147.06 | $20.00 |
Enterprise Value | $275.41B | $13.38B |
Dividend Yield | 2.01% | 6.87% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →